Director/PDMR Shareholding

e-Therapeutics plc

(the "Company")

Director/PDMR Shareholding

Oxford and Newcastle, UK, 21 January 2015 - e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that the Company was notified today that Steve Medlicott, Finance Director, purchased 150,000 ordinary shares in the Company ("Ordinary Shares") at 25.25 pence per share on 21 January 2015. Following the purchase, Mr Medlicott's resultant direct beneficial interest is 250,000 Ordinary Shares, representing 0.09% of the total issued share capital of the Company.

- Ends -

Contacts:

e-Therapeutics plc

Steve Medlicott, Finance Director

Tel: +44 (0) 1993 883125

www.etherapeutics.co.uk  

N+1 Singer

Aubrey Powell / Jen Boorer

Tel: +44 (0)20 7496 3000

www.n1singer.com 

Instinctif Partners

Melanie Toyne-Sewell / Emma Barlow

Tel: +44 (0) 20 7457 2020

Email: [email protected]

About e-Therapeutics plc

e-Therapeutics is an AIM-quoted drug discovery and development company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is currently focused in cancer and disorders of the nervous system.

e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.